RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will report second-quarter 2026 financial results after U.S. markets close Tuesday, Aug. 11, as the biopharmaceutical company continues development of its lead hypertension drug candidate, lorundrostat.
Mineralys will hold a conference call at 4:30 p.m. ET the same day to discuss results for the quarter ended June 30.
Domestic participants can access the call at 1-877-704-4453, while international participants can dial 1-201-389-0920. The conference ID is 13760792. A live webcast will be available at https://viavid.webcasts.com/starthere.jsp?ei=1764562&tp_key=8aad48a513 and through the “News & Events” page of the company’s investor website.
Radnor-based Mineralys is developing therapies targeting hypertension and aldosterone-related conditions, including chronic kidney disease and obstructive sleep apnea.
Its lead candidate, lorundrostat, is an investigational oral aldosterone synthase inhibitor.
Additional information about Mineralys is available at https://mineralystx.com.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.